Twist Bioscience reports Q3 EPS ($1.01), consensus ($1.14)

Reports Q3 revenue $63.74M, consensus $60.54M. “We reported record revenue again this quarter, with our core business, comprised of SynBio and NGS, delivering very strong results,” said Emily Leproust, CEO and co-founder of Twist Bioscience. “Significantly, our Wilsonville site manufactured and shipped the vast majority of our genes, gene fragments and oligo pools, with the new team performing well. We continued to expand our NGS portfolio with the launch of our RNA sequencing portfolio targeting the substantial research market.”